- Zacks
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug
Following a fruitful meeting with the FDA, Ultragenyx (RARE) plans to seek accelerated approval for UX111 for the treatment of Sanfilippo syndrome type A.
- Zacks
Ultragenyx (RARE) Posts New Data From Bone Disease Study
Ultragenyx's (RARE) pipeline candidate setrusumab shows sustained reductions in fracture rates in patients with osteogenesis imperfecta in new data from the Orbit study.
- Zacks
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
